In 2012 as well, in the Nordic trial Malmström et al.5 found that 6-week standard radiotherapy associates with poor outcome in GBM patients >70 years (median OS 6 months) and that temozolomide alone, especially in MGMT-methylated patients, or hypofractionated radiotherapy 34/3.4 Gy gave better results (median OS 8.3 and 7.5 months). The gene discussed is MGMT; the disease is glioblastoma.